Australia's most trusted
source of pharma news
Posted 18 October 2024 AM
Novo Nordisk is updating insulin, finding a way to make the drug responsive to different blood levels of glucose, making the treatment safer for people with diabetes.
In an article published in Nature, Glucose-sensitive insulin with attenuation of hypoglycaemia, a team led by researchers from Novo Nordisk and including people from the University of Bristol and CRO Apigenex described the modified form of insulin, which has a switch to alter the activity of the molecule based on blood glucose concentration.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.